Human papillomavirus: A review

Dermatologic Clinics

Volumn 20, Issue 2, 2002, Pages 315-331

  Brentjens, Mathijs H ^a   Yeung Yue, Kimberly A ^a   Lee, Patricia C ^a   Tyring, Stephen K ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTIVIRUS AGENT; CIDOFOVIR; DICHLOROACETIC ACID; FLUOROURACIL; IMIQUIMOD; INTERFERON; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID;

CLINICAL FEATURE; HUMAN; PRIORITY JOURNAL; REVIEW; VERRUCA VULGARIS; VIRUS CLASSIFICATION; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS; WART VIRUS; CONDYLOMA ACUMINATUM; PAPILLOMA VIRUS;

CONDYLOMATA ACUMINATA; HUMANS; PAPILLOMAVIRIDAE;

EID: 0035986491     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(01)00028-6     Document Type: Article

References (184)

1. Papillomaviruses and their replication
2. Human papillomavirus and human disease
3. The E1 helicase of human papillomavirus type 11 binds to the origin of replication with low sequence specificity
4. In vitro synthesis of oncogenic human papillomaviruses requires episomal genomes for differentiation-dependent late expression
5. Replication-associated activities of purified human papillomavirus type 11 E1 helicase
6. Localization and analysis of bovine papillomavirus type 1 transforming functions
7. Bovine papilloma virus (BPV)-encoded E2 protein enhances binding of E1 protein to the BPV replication origin
8. Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin
9. Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames
10. Identification of the origin of replication of bovine papillomavirus and characterization of the viral origin recognition factor E1
11. Cooperative assembly of the bovine papilloma virus E1 and E2 proteins on the replication origin requires an intact E2 binding site
12. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins
13. Bovine papilloma virus-transformed cells contain multiple E2 proteins
14. Suppression of cellular proliferation by the papillomavirus E2 protein
15. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network
16. The E5 transforming proteins of the papillomaviruses
17. Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain
18. The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression
19. Pathogenesis of cancer of the cervix
20. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway
21. A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation
22. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells
23. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
24. Cell cycle control and cancer
25. Purification and characterization of human papillomavirus type 16 E7 protein with preferential binding capacity to the underphosphorylated form of retinoblastoma gene product
26. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G-cell cycle arrest
27. Both e6 and e7 oncoproteins of human papillomavirus 16 inhibit i-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells
28. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes
29. Human papillomavirus infections: Epidemiology, pathogenesis, and therapy
30. Epidemiology of genital human papillomavirus infection
31. Natural history of genital warts
32. Pathogenesis of viral infections
33. Human papillomavirus: Epidemiology, transmission, and pathogenesis
34. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions
35. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females
36. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV)
37. Status of local cellular immunity in interferon-responsive and -nonresponsive human papillomavirus-associated lesions
38. Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas
39. Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers
40. Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites
41. The oncogenic role of human papillomavirus proteins
42. Cooperation between papillomavirus and chemical cofactors in oncogenesis
43. Typing of human papillomavirus by pyrosequencing
44. Detection of human papillomavirus DNA in keratoacanthomas by polymerase chain reaction
45. Syrjanen: No evidence of human papillomavirus DNA in actinic keratosis
46. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis
47. Detection of human papillomavirus DNA in nongenital seborrhoeic keratoses
48. Second International Workshop on the Epidemiology of Cervical Cancer and Human Papillomaviruses
49. Detection of human papillomavirus DNA in squamous cell carcinoma of the nail bed and finger determined by polymerase chain reaction
50. Presence of human papilloma virus type 16 DNA sequences in human nonmelanoma skin cancers
51. Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis
52. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin
53. Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses
54. Human papillomavirus type 17 transcripts expressed in skin carcinoma tissue of a patient with epidermodysplasia verruciformis
55. Human papilloma virus infection and skin cancer in renal allograft recipients
56. Detection of human papillomavirus type 5 DNA in skin cancers of an immunosuppressed renal allograft recipient
57. Detection and typing of human papillomaviruses by means of polymerase chain reaction and fragment length polymorphism in male genital lesions
58. Human papillomavirus and cancer: The epidemiological evidence
59. The presence of HPV DNA in cervical cancer: Correlation with clinico-pathologic parameters and prognostic significance-10 years' experience at the Department of Obstetrics and Gynecology of the Mainz University
60. Human papillomavirus as a prognostic factor in carcinoma of the penis: Analysis of 82 patients treated with amputation and bilateral lymphadenectomy
61. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites
62. The presence of HPV 16, 18 and p53 immunohistochemical staining in tumor tissue of Israeli Jewish women with cervical and vulvar neoplasia
63. Association of multiple human papillomavirus types with vulvar neoplasias
64. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: Analysis of primary tumors and lymph nodes
65. Detection and typing of human papillomavirus in anal epidermoid carcinomas: Sequence variation in the E7 gene of human papillomavirus Type 16
66. Plantar verrucae and HIV infection
67. HPV subtype analysis in lower genital tract neoplasms of female renal transplant recipients
68. Human papillomavirus and lower genital neoplasia in renal transplant patients
69. High prevalence of oncogenic human papillomavirus in the genital tract of women with human immunodeficiency virus
70. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients
71. Role of human papillomaviruses in cutaneous and oral manifestations of immunosuppression
72. A novel genital human papillomavirus (HPV), HPV type 74, found in immunosuppressed patients
73. Frequency of mucosal HPV DNA detection (types 6/11, 16/18, 31/35/51) in skin lesions of renal transplant patients
74. Treatment with interferon for genital HPV in HIV-positive and HIV-negative women
75. A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients
76. Prevalence of skin diseases among adolescents 12-16 years of age
77. Clinical features and age distribution of patients with HPV-induced common warts
78. Common viral skin problems of childhood: Warts and molluscum
79. Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic
80. Human papillomaviruses and anogenital disease
81. Estimates of the worldwide incidence of eighteen major cancers in 1985
82. Implementing recommendations for the early detection of breast and cervical cancer among low-income women
83. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
84. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer
85. Natural history of cervicovaginal papillomavirus infection in young women
86. Reproductive variables and risk of uterine cervical cancer in Norwegian registry data
87. Human papillomavirus infections in women with HIV disease: Prevalence, risk, and management
88. The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection
89. Human papillomavirus and invasive cervical cancer in Brazil
90. Smoking habits and risk of cancers other than lung cancer: 28 Years' follow-up of 26,000 Norwegian men and women
91. Cervical intraepithelial neoplasia and cervical cancer
92. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer
93. Therapeutic efficacy and complications of excisional biopsy of condyloma acuminatum
94. Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision
95. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: A prospective study
96. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: Is it an alarm for disease recurrence?
97. Detection of human papillomavirus by the polymerase chain reaction in histologically normal penile skin adjacent to penile warts
98. Recurrence of dysplasia after loop electrosurgical excision procedures with longterm follow-up
99. Treatment of external genital warts: A randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation
100. Density of viral particles in pre and post Nd: YAG laser hyperthermia therapy and cryotherapy in plantar warts
101. Treating vaginal and external anogenital condylomas with electrosurgery vs CO2 laser ablation
102. Genital warts and their treatment
103. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts
104. Absence of human papillomavirus DNA in the plume of erbium: YAG laser-treated warts
105. Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid
106. Cryotherapy compared with trichloroacetic acid in treating genital warts
107. Autogenous vaccine: The best therapy for perianal condyloma acuminata?
108. Condyloma eradication: Self-therapy with 0.15-0.5% podophyllotoxin versus 20-25% podophyllin preparations: An integrated safety assessment
109. Quercetin and kaempherol: An argument against the use of podophyllin?
110. Selftreatment of female external genital warts with 0.5% podophyllotoxin cream (Condyline) vs weekly applications of 20% podophyllin solution
111. A single-blind study of podophyllotoxin cream 0.5% and podophyllotoxin solution 0.5% in male patients with genital warts
112. Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts
113. A randomized, double-blind, placebo-controlled trial of 5-fluorouracil for the treatment of cervicovaginal human papillomavirus
114. Topical 5-fluorouracil in the treatment of cervical human papillomavirus infection
115. Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrophilic gel: A placebo-controlled double-blind study
116. Interferon as an adjuvant treatment for genital condyloma acuminatum
117. Development of intralesional therapy with fluorouracil/adrenaline injectable gel for management of condylomata acuminata: Two phase II clinical studies
118. The eradication of intraurethral condyloma acuminata with 5 per cent 5-fluorouracil cream
119. Treatment of vaginal condylomata acuminata by weekly topical application of 5-fluorouracil
120. Resolution of recalcitrant human papillomavirus gingival infection with topical cidofovir
121. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue
122. Treatment of verruca vulgaris with topical cidofovir
123. Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV/AIDS. A pilot study
124. Phase I/II Study of Cidofovir Gel for Refractory Condyloma Acuminatum in Patients with HPV Infection
125. Efficacy and tolerability of topical 1% cidofovir cream for the treatment of external anogenital warts in HIV-infected persons
126. No apparent effect of cidofovir in epidermodysplasia verruciformis
127. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)
128. Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirus-associated lesions
129. Serum 2′-5′-oligoadenylate synthetase levels and clinical response to interferon-beta therapy in women with genital human papillomavirus infection
130. Efficacy trial of topically administered interferon gamma-1 beta gel in comparison to laser treatment in cervical intraepithelial neoplasia
131. Topic and systemic administration of natural alfa interferon in the treatment of female and male HPV genital infections
132. Human leukocyte derived interferon-alpha in a hydrophilic gel for the treatment of intravaginal warts in women: A placebo-controlled, double-blind study
133. Human leukocyte interferonalpha versus podophyllotoxin in cream for the treatment of genital warts in males: A placebo-controlled, double-blind, comparative study
134. Human leukocyte interferonalpha in cream, for the treatment of genital warts in Asian women: A placebo-controlled, double-blind study
135. A randomized, doubleblind trial of parenteral low dose versus high dose interferon-beta in combination with cryotherapy for treatment of condyloma acuminatum
136. Randomized placebo-controlled evaluation of intramuscular interferon beta treatment of recurrent human papillomavirus
137. Tolerance and efficacy of recombinant human interferon gamma in the treatment of refractory genital warts
138. Systemic alpha-interferon (Wellferon) treatment of genital human papillomavirus (HPV) type 6, 11, 16, and 18 infections: Double-blind, placebo-controlled trial
139. Interferon therapy for condylomata acuminata
140. Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived)
141. Natural interferon alfa for treatment of condylomata acuminata
142. Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum
143. Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection
144. Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata: A phase 3 clinical study
145. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris
146. A randomized phase II study comparing four different interferon therapies in patients with recalcitrant condylomata acuminata
147. Direct medical costs for surgical and medical treatment of condylomata acuminata
148. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod
149. Treatment of genital warts with an immune-response modifier (imiquimod)
150. Imiquimod, a patientapplied immune-response modifier for treatment of external genital warts
151. Self-administered topical 5% imiquimod cream for external anogenital warts
152. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day
153. Self-administered topical 5% imiquimod cream for external anogenital warts in adolescent girls
154. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%
155. Treatment of facial verrucae with topical imiquimod cream in a patient with human immunodeficiency virus
156. Imiquimod: A new possibility for treatment-resistant verrucae planae
157. Lip papillomatosis in immunodeficiency: Therapy with imiquimod
158. Topical imiquimod for recalcitrant facial flat warts
159. Successful treatment of actinic keratosis with imiquimod cream 5%: A report of six cases
160. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum
161. Imiquimod 5% cream in the treatment of Bowen's disease
162. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day
163. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions
164. Cervical cancer vaccines: Emerging concepts and developments
165. Papillomavirus research update: Highlights of the Barcelona HPV 2000 International Papillomavirus Conference
166. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7
167. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts
168. Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts
169. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
170. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer
171. Treatment of recurrent penile condylomata acuminata with external application and intraurethral instillation of bacillus Calmette-Guerin
172. Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials
173. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
174. Papillomavirus-like particle vaccines
175. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
176. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16
177. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
178. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination
179. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer
180. HPV DNA testing in cervical cancer screening: Results from women in a high-risk province of Costa Rica
181. A novel and rapid PCR-based method for genotyping human papilloma viruses in clinical samples